Is it equivalent?
Lipodox® for treatment of recurrent ovarian cancer did not appear to have equivalent efficacy compared to Doxil®. A prospective clinical study is warranted before Lipodox® can be deemed equivalent substitution for Doxil®.
Lung CD4 counts in patients with HIV-1 infection may provide an independent predictor of survival.